Venturi Wealth Management LLC Acquires 1,193 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Venturi Wealth Management LLC raised its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 710.1% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 1,361 shares of the medical research company’s stock after acquiring an additional 1,193 shares during the quarter. Venturi Wealth Management LLC’s holdings in IQVIA were worth $267,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Smith Group Asset Management LLC acquired a new stake in IQVIA in the 4th quarter worth approximately $1,616,000. Simplify Asset Management Inc. lifted its stake in shares of IQVIA by 67.8% in the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after buying an additional 3,894 shares during the last quarter. Nordea Investment Management AB boosted its holdings in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after buying an additional 452,029 shares during the period. Hickory Asset Management Inc. acquired a new position in IQVIA in the 4th quarter valued at $941,000. Finally, Fifth Third Bancorp raised its holdings in IQVIA by 13.0% in the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock worth $2,590,000 after acquiring an additional 1,521 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insider Activity

In other IQVIA news, Director John G. Danhakl purchased 1,275 shares of the company’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was purchased at an average cost of $200.58 per share, with a total value of $255,739.50. Following the acquisition, the director now directly owns 1,275 shares of the company’s stock, valued at approximately $255,739.50. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 1.60% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on IQV shares. Barclays lowered their price target on IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd. Bank of America lowered their target price on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Truist Financial reiterated a “buy” rating and set a $263.00 price target (up from $261.00) on shares of IQVIA in a report on Monday, February 10th. Morgan Stanley raised their price objective on shares of IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Finally, Robert W. Baird dropped their target price on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 21st. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $251.22.

IQVIA Trading Down 1.3 %

IQV stock opened at $194.01 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a market cap of $34.16 billion, a P/E ratio of 25.87, a P/E/G ratio of 1.98 and a beta of 1.48. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73. The business’s 50 day moving average is $199.86 and its 200-day moving average is $216.95.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities analysts anticipate that IQVIA Holdings Inc. will post 10.86 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.